OBJECTIVES: To evaluate the economic feasibility of using Hypoxenum in comparison to not administering it, in the complex treatment of angina pectoris. METHODS: A randomized prospective controlled study on typical practice of 200 patients who received comprehensive treatment of angina pectoris with or without Hypoxenum, was performed to assess direct medical costs and cost effectiveness ratio. RESULTS: Overall cost of treatment of one patient with angina pectoris within 15 days in the hospital with Hypoxenum in the combined therapy was 5 968.94 rubles. The total cost of treatment of one patient in group of typical treatment of angina pectoris was 5 294.10 rubles. As the criteria of the effectiveness of treatment were taken: indicators of performed work, threshold power, exercise tolerance test. At the end indicators of the Hypoxenum group and the typical practice group were: work performed: increased of 25.9 kJ and 15.1 kJ, respectively (differences were significant, p<0.05), the threshold power was 25.5 Watt and 13,2 Watt, respectively. Increased exercise tolerance was observed in 49% of patients in the Hypoxenum group and in 28% of patients in the control group. The cost- effectiveness ratio for the criterion of completed work was 230.4 rubles and 350.6 rubles, for threshold power - 234.07. and 401.06 rubles, for increasing of exercise tolerance - 12 181.51 rubles and 18 907.50 rubles for Hypoxenum and typical practice, respectively.  CONCLUSIONS: The cost-effectiveness study on the dynamics of tolerance of exercise compared to typical practice, revealed that treatment of angina pectoris, with Hypoxenum is a clinically and economically feasible.